Patience to win, page-360

I don't understand the terrible reaction that has ensued this announcement - the company is still making money with room to grow. Though the 15M of options issued is a surprise given the market conditions, i doubt Conidi will refuse them.

From the presentation, doctors are already starting to be cautious around referring patients to radiology to avoid scrutiny - makes sense and there might be more pain to go. Yet taking out the one off acquisition cost, the NPBT is only $5.2M down from $7.3M due to increased interest charges and a drop in CTs. This isn't terrible, they are still making money, share price did not deserve a 85% drop from the high.

Employee and contractor benefits increased 80% and revenue only increased 58%... i think there is an opportunity to reduce this cost in terms of re structuring the new acquisitions and existing centres - considering these costs were $47.5M this could easily improve bottom line.

Enlitic is meant to increase the efficiency of the company further- reducing time for radiologists to diagnose scans, meaning less radiologists potentially. Enlitic is also meant to provide a diagnosis more accurate than what radiologists can predict themselves and CAJ has exclusive rights in AUS/NZ. However I'm not sure if people booking in for a radiology scan would even know this to look out for this technology and go to CAJ's centres because of it.

I don't think its time to panic, the company is still making money, debt levels are in control, in an industry which should organically grow once more after this MBS review sets in (not to mention international opportunities). Share price in my opinion is oversold. DYOR